Northstrive Biosciences Files New Patent Applications

ELEVAI Labs Inc. ( (ELAB) ) has shared an update.

On April 29, 2025, Northstrive Biosciences Inc. announced the filing of four new patent applications for their candidates EL-22 and EL-32, targeting both the animal market and obesity treatment. These filings aim to enhance Northstrive’s IP portfolio and support the development of their probiotic platform, potentially transforming obesity care and entering the animal health market.

Spark’s Take on ELAB Stock

According to Spark, TipRanks’ AI Analyst, ELAB is a Underperform.

ELEVAI Labs Inc. faces significant challenges with negative financial performance, adverse technical indicators, and a troubling valuation. Despite a strong equity position, the lack of revenue and negative cash flow highlight operational struggles. The absence of positive catalysts or corporate events directly affecting ELAB further limits the stock’s appeal.

To see Spark’s full report on ELAB stock, click here.

More about ELEVAI Labs Inc.

Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., is a biopharmaceutical company focused on developing and acquiring innovative aesthetic medicines. Their lead asset, EL-22, uses an engineered probiotic approach to address muscle preservation during obesity treatments. PMGC Holdings Inc. is a diversified holding company managing a portfolio through strategic acquisitions and investments across various industries.

YTD Price Performance: -85.71%

Average Trading Volume: 522,552

Technical Sentiment Signal: Buy

Current Market Cap: $2.03M

See more insights into ELAB stock on TipRanks’ Stock Analysis page.